Similar articles

• ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck.

  Pivot X; ESMO Guidelines Task Force. Pivot X, et al. Ann Oncol. 2003 Jul;14(7):1014-5. doi: 10.1093/annonc/mdg295. Ann Oncol. 2003. PMID: 12853341 No abstract available.
• Squamous cell carcinoma of the head and neck: ESMO clinical Recommendations for diagnosis, treatment and follow-up.

  Pivot X, Felip E; ESMO Guidelines Working Group. Pivot X, et al. Ann Oncol. 2008 May;19 Suppl 2:ii79-80. doi: 10.1093/annonc/mdn097. Ann Oncol. 2008. PMID: 18456779 No abstract available.
• Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Grégoire V, et al. Ann Oncol. 2010 May;21 Suppl 5:v184-6. doi: 10.1093/annonc/mdq185. Ann Oncol. 2010. PMID: 20555077 No abstract available.
• Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).

  Azoury SC, Gilmore RC, Shukla V. Azoury SC, et al. Discov Med. 2016 Jun;21(118):507-16. Discov Med. 2016. PMID: 27448787 Review.
• Management of advanced stage squamous cell carcinoma of the head and neck.

  Forastiere AA. Forastiere AA. Am J Med Sci. 1986 Jun;291(6):405-15. doi: 10.1097/00000441-198606000-00007. Am J Med Sci. 1986. PMID: 3521275 Review.